Physician profile
Jon Logan Aaron
NPI 1811702467
$2,263.49
in general payments reported to CMS, 2019-2025
39 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.49 |
| Education | $182.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $312.38 | 2025 | Imfinzi, Datroway, Lynparza |
| Beone Medicines USA, INC. | $158.95 | 2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $132.23 | 2025 | Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $119.93 | 2025 | |
| Janssen Biotech, INC. | $117.85 | 2025 | Rybrevant, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $99.00 | 2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $97.73 | 2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $88.92 | 2025 | Monoferric |
| Seagen INC. | $83.00 | 2025 | |
| Celgene Corporation | $82.15 | 2025 | Reblozyl |
| Caris Mpi, INC. | $76.57 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $67.46 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Sumitomo Pharma America, INC. | $54.49 | 2025 | Orgovyx |
| Lilly USA, LLC | $52.85 | 2025 | Verzenio, Jaypirca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.26 | 2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.70 | 2025 | |
| Array Biopharma INC | $47.29 | 2025 | Braftovi, Tukysa, Mektovi |
| Genentech USA, INC. | $43.02 | 2025 | Tecentriq, Venclexta |
| Regeneron Healthcare Solutions, INC. | $42.23 | 2025 | Libtayo |
| Sobi, INC | $41.83 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.26 | 2025 | |
| Shield Therapeutics INC | $36.05 | 2025 | |
| Exelixis INC. | $29.74 | 2025 | Cabometyx |
| Geron Corporation | $28.26 | 2025 | Rytelo |
| Iovance Biotherapeutics, INC. | $26.78 | 2025 | Amtagvi |
| Adaptive Biotechnologies Corporation | $26.01 | 2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $25.71 | 2025 | Ultomiris |
| Stemline Therapeutics INC. | $23.22 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $22.64 | 2025 | |
| Immunocore Limited | $21.72 | 2025 | Kimmtrak |
| Pharmaessentia USA Corporation | $21.03 | 2025 | Besremi |
| Genzyme Corporation | $20.61 | 2025 | |
| Incyte Corporation | $19.98 | 2025 | Jakafi |
| Agios Pharmaceuticals, INC. | $17.99 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $17.50 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $17.02 | 2025 | Blenrep, Ojjaara |
| Kite Pharma, INC. | $16.93 | 2025 | Yescarta |
| Fennec Pharmaceuticals, INC. | $16.11 | 2025 | Fyarro |
| Beigene USA, INC. | $16.09 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.